Khosla Ventures leads $38M seed round for organoid startup Vivodyne
Khosla Ventures is leading a seed round for a new biotech that aims to use artificial intelligence to jump into the world of organoids.
Vivodyne announced the $38 million seed financing Wednesday morning, touting its platform’s ability to produce human-like tissue at every stage of drug development. The goal, CEO Andrei Georgescu told Endpoints News, is to slash preclinical testing times by reducing the need for animal testing, and use the platform to learn how compounds will interact with human cells at scale before actually testing them in people.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.